Immune Pharmaceuticals amends licensing agreement with Endo Pharmaceuticals

Editorial Checklist Reviewed
Immune Pharmaceuticals Inc.Jul 8 2015NewsGuard 100/100 Score

Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) announced today that it has amended its 2003 Licensing Agreement with Endo Pharmaceuticals Inc., a subsidiary of Endo International plc. As a result, Immune will transfer to Endo its previously licensed patents related to the use of topical lidocaine in acute and chronic back pain and Endo will grant Immune a royalty-free, non-exclusive, fully transferable license to those patents. Endo will pay undisclosed milestones to Immune if Endo receives a back pain indication for a lidocaine-based product, as per the original 2003 Licensing Agreement.

Immune will re-gain full exclusive rights to develop, commercialize and license LidoPain®, a high-dose lidocaine patch for the treatment of acute pain. LidoPain® is currently in Phase II clinical development.

Source:

Immune Pharmaceuticals Inc.

Posted in: Business / Finance | Medical Patent News | Pharmaceutical News

Tags: , , , , , , , , , , ,

Comments (0)

Suggested Reading

Physical activity and positive affect boost cognition in women with fibromyalgia despite pain
Avadel Pharmaceuticals announces publication of RESTORE data highlighting challenges with twice-nightly oxybates and strong patient preference for once-nightly LUMRYZ™ dosing (sodium oxybate) extended-release oral suspension (CIII)
Western diet accelerates endometriosis growth and disrupts gut health
Telehealth mindfulness interventions significantly improve chronic pain outcomes for veterans
It's official! Men and women experience and manage pain differently
How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics
Triptans better at relieving migraine pain than recently marketed and more expensive drugs
A novel approach to photosynthetic production of high-value compounds

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Weight loss drug semaglutide may offer relief for knee arthritis pain